Association analysis of monoamine oxidase A gene and bipolar affective disorder in Han Chinese by Lin, Yi-Mei J et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Behavioral and Brain Functions
Open Access Research
Association analysis of monoamine oxidase A gene and bipolar 
affective disorder in Han Chinese
Yi-Mei J Lin1, Fabian Davamani1, Wei-Chih Yang2, Te-Jen Lai3,4 and H 
Sunny Sun*1
Address: 1Institute of Molecular Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, 2Institute of Biomedical Sciences, 
Academia Sinica, Taipei, Taiwan, 3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan and 4Department of Psychiatry, Chung 
Shan Medical University Hospital, Taichung, Taiwan
Email: Yi-Mei J Lin - joyl@ms32.url.com.tw; Fabian Davamani - fabiandavamani@yahoo.com; Wei-Chih Yang - wcyang@ibms.sinica.edu.tw; 
Te-Jen Lai - tejenlai@hotmail.com; H Sunny Sun* - hssun@mail.ncku.edu.tw
* Corresponding author    
Abstract
Background: Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in degrading
several different biological amines, including serotonin. Although several pieces of evidence
suggested that MAOA is important in the etiology of bipolar affective disorder (BPD), associations
for markers of the MAOA gene with BPD were not conclusive and the association has not been
investigated in Taiwanese population. This study was designed to illustrate the role of MAOA in
the etiology of BPD in Han Chinese.
Methods: Two markers, a dinucleotide polymorphism in exon 2 and a functional uVNTR on the
promoter of the MAOA gene, were used to study the genetic association in 108 unrelated patients
with BPD and 103 healthy controls. Allelic distributions of two polymorphisms were analyzed and,
caused the MAOA located at X chromosome, haplotype association was performed using
haplotype unambiguously assigned in male participants.
Results: While no difference in allelic distributions of two MAOA polymorphisms was found, the
risk haplotype 114S was associated with BPD in male patients (P = 0.03). The significance, however,
was not found in female patients with 114S haplotype.
Conclusion: Results from this study suggest that MAOA may have a gender-specific and small
effect on the etiology of BPD in Taiwan. Due to the limited sample size, results from this study need
to be confirmed in replicates.
Background
Bipolar affective disorder (BPD) is a common severe
mood disorder characterized by manic and depressive epi-
sodes; it has an estimated lifetime prevalence of 0.1~1%
in various populations, including Chinese [1]. In spite of
previous studies (review by [2]) strongly suggested that
genetic factors were involved in the etiology of BPD, the
classical strategy of linkage analysis has been fraught with
difficulty in searching for the predisposing genes. As the
"monoamine hypothesis" proposes that the underlying
biological basis for depression is depletion of central
noradrenergic, serotonergic, and dopaminergic systems
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[3], thus genes implicated in the metabolism or kinetics of
monoamine neurotransmitter system, including the sero-
tonin (5-HT) and dopamine (DA), are good candidates
for studying the association with affective disorder [4].
Monoamine oxidase (MAO) is an enzyme expressed in
the outer mitochondrial membrane; it catalyzes the degra-
dation of biological amines [5]. There are two forms of
monoamine oxidase, MAOA and MAOB, each with a dif-
ferent substrate and inhibitor specificities. The two MAO
genes are localized tail to tail on Xp11.4-p11.23, identi-
fied using in situ hybridization [6], and span at least 60 kb.
They consist of 15 exons and have identical exon-intron
organization [7]. Several pieces of evidence have sug-
gested that MAOA in particular is important in human
behavior and physiology. The first association of the
MAOA gene with psychiatric disease was reported in a
study of a large family in Holland [8]; all the affected
males showed characteristically abnormal behavior:
aggression and sometimes violence. Using genetic linkage
analysis, researchers assigned the locus for this disorder to
an MAO gene mutation on the X chromosome. MAOB
activity was normal in this family; the unusual behavior
pattern was traced to a mutation in MAOA [8,9]. The
MAOA-gene-knockout mice showed behavioral alteration
[10]. MAOA inhibitors have been effectively used in clin-
ical trials to treat BPD, and MAOA is a target for some anti-
depressant drugs [11,12]. These studies strongly suggested
the possible involvement of MAOA in the etiology of
BPD. Polymorphisms of the MAOA gene have been used
to extensively study its association with several psychiatric
conditions, such as BPD [13], depression [14], and aggres-
sion-related traits [15]. These polymorphisms includes a
highly polymorphic dinucleotide (CA) microsatellite
repeat in the second exon [16], a 23-bp VNTR in intron 1
[17], a 30-bp functional uVNTR (MAOA-uVNTR) that is
~1.2 Kb upstream of the coding region [18], an RFLP pol-
ymorphism (Fnu4H1 and EcoRV) [19], and some single
nucleotide polymorphisms (SNPs) including rs1799835,
rs6323, and rs1465108 [20,21].
The association of MAOA polymorphisms with BPD has
been contradictory in different populations. For example,
while studies conducted in Germany [22], the U.S.A. [23],
Canada [24], and China [25] have shown no associations
in their overall samples, positive associations have been
reported from studies performed in Japan [26] and the
U.K. [13]. Furthermore, studies done in France and Swit-
zerland [27] and the U.K. [28] have reported positive asso-
ciations in females but not in males. Another study in
Japan revealed no association between MAOA and BPD
for the overall sample as well as for either sex studied sep-
arately [29]. To illustrate the role of MAOA in the patho-
genesis of BPD patients in Taiwan, we have conducted a
genetic association study and analyzed the distributions
of both promoter uVNTR and the (CA) repeat polymor-
phisms in BPD patients and controls. Further examina-
tion into the effect of risk haplotype has taken advantage
of the fact that the MAOA  gene is on X chromosome;
therefore males are hemizygotes and the haplotype can be
unambiguously assigned in male individuals. Our data
revealed a risk haplotype association of MAOA polymor-
phisms and BPD in male patients only thus it suggests that
MAOA may have a gender-specific and small effect in the
etiology of BPD in Taiwan.
Methods
Sample collection and DNA preparation
The subjects were all Han Chinese who had been col-
lected, beginning in 1998, for series studies investigating
the involvement of serotonergic genes in the pathogenesis
of BPD [30-33]. Patients and controls were interviewed by
experienced psychiatrists after the study procedure had
been fully explained and information on general demo-
graphic data, such as age, sex, and ethnicity, was obtained.
In Briefly, 108 (59 males and 49 females) unrelated BPD
patients were recruited from direct clinical interviews by a
treating clinician according to the DSM-IV criteria for
diagnoses of lifetime major depressive disorder and bipo-
lar I. Additional information required to reach a diagnosis
was also collected from all clinical and hospital records
where available. Furthermore, information on family his-
tory of the disease and co-morbidity with other psychiat-
ric disorders, neurological disorders, or medical problems
were also collected. Only one patient was found to have
co-morbid psychiatric condition with alcohol abuse.
Although about 10% of the patients have medical prob-
lems like hypertension or diabetes, the diseases are com-
mon in general population as well. Thus the information
on co-morbidity was not considered as inclusion or exclu-
sion criteria in this study. One hundred three (55 males
and 48 females) controls were recruited from volunteers
with no family or personal history of major affective dis-
order and were matched to patients based on ethnic or
geographic origin, sex, and age. The gender ratios are iden-
tical in both case and control groups (male to female is
53% to 47%). This study was approved by the University
Ethics Committee and the standards established by the
National Science Council, Taiwan. Written informed con-
sent was obtained from all participants.
Genomic DNA was prepared from approximately 10 ml of
peripheral blood using the standard salt-precipitation
method [34] or a kit (InstaGene Whole Blood kit; Biorad,
Hercules, CA, USA) according to the manufacturer's pro-
tocol.
Polymorphism genotyping
The forward primer 5'-ACAGCCTGACCGTGGAGAAG-3'
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were used to amplify a fragment that contained the 30-bp
repeat uVNTR polymorphisms [18]. PCR was performed
in a 25-μl reaction containing 100 ng of genomic DNA,
250 μM of dNTPs, 0.2 μM of primers, and 0.5 units of Taq
DNA polymerase (Promega, Madison, WI, USA) in 1×
buffer with 1.5 mM of MgCl2. The condition set in the
thermocycler was pre-denaturation for 3 min at 95°C, 1
min at 95°C, 1 min at 64°C, and 1 min at 72°C for 35
cycles, and then a final extension for 5 min at 72°C. The
PCR products were separated using electrophoresis on a
2.5% agarose gel, visualized using ethidium bromide
staining, and documented.
The MAOA-CA microsatellite polymorphism was ampli-
fied with the primer set FAM-5'-AGAGACTAGACAAGTT-
GCAC-3' and 5'-CACTATCTTGTTAGCTCAC T-3' [16].
Amplification was performed in 10-μl reaction containing
40–50 ng of genomic DNA, 200 μM of dNTP, 0.15 μM of
primers, and 0.25 units of Taq DNA polymerase
(Promega) in 1× buffer with 1.5 mM of MgCl2. Cycling
parameters were pre-incubation for 3 min at 95°C, and
then 35 cycles of 30 sec at 95°C, 45 sec at 56°C, 45 sec at
72°C, and a final incubation step of 7 min at 72°C. The
PCR products were analyzed using a genetic analyzer
(ABI310; Applied Biosystems). Capillary electrophoresis
was performed by mixing 1 μl of the PCR product mix
with 11.5 μl of formamide and 0.5 μl of size markers,
heating the mixture at 95°C for 5 min, and then quickly
cooling it on ice. Fourteen microliters of each sample was
loaded onto a capillary polymer and run for 30 min. Prod-
ucts of different size were separated using polymer capil-
lary electrophoresis, and the length of each PCR product
was determined from the size markers. Data were col-
lected and analyzed using computer software (ABI GeneS-
can; Applied Biosystems). To avoid genotyping errors,
genotypes were scored independently by two investigators
and checked for confirmation. In addition, discrepant
genotypes were retyped to ensure the correct genotypes for
final data analysis.
Statistical analysis
Allelic distributions between patients and matched con-
trols were analyzed using the χ2 test and Fisher's exact test
(SAS, version 8; SAS, Cary, NC, USA). Hardy-Weinberg
Equilibrium was separately calculated for each gender and
examined by χ2 test implemented in the SAS program. For
allelic distributions analysis, MAOA-CA and -uVNTR pol-
ymorphisms were grouped into several classes to mini-
mize the allele number. Four major alleles of MAOA-CA
with a frequency larger than 5% were chosen, and the
other rare alleles (frequency less than 5%) were pooled
together as a single allele. MAOA-uVNTR was classified in
accordance with a previous taxonomy [18]. In addition,
the linkage disequilibrium estimation (LD) and haplo-
types construction using the expectation-maximization
(EM) method were performed in female groups
(SNPAlyze: SNP and Disease Association Analysis soft-
ware version 4.1; Dynacom Co., Ltd. Kanagawa, Japan).
Odds ratio and power estimation were estimated using
SAS and Power Analysis and Sample Size (PASS) 2005
software (NCSS, Kaysville, UT, USA), respectively. The sig-
nificance level for all statistical tests was 0.05 and we
applied Bonferroni corrections for multiple tests in the
association study.
Results
Polymorphism genotyping and single-locus association 
analysis
Two polymorphisms, MAOA-CA and -uVNTR, were geno-
typed in our case-control participants. For the microsatel-
lite marker MAOA-CA, we found 9 alleles ranging from
106- to 126-bp with 2 bases increments (alleles 126–114
correspond to alleles A0–A6 of [28]). Interestingly, we
found no participant with 122-bp and 124-bp alleles. For
MAOA-uVNTR in the promoter region, we identified 3
alleles corresponding to 3, 4, and 5 repeats in our popula-
tion. The distributions of alleles for each polymorphism
are presented in Table 1. The genotype frequencies of
MAOA-CA (9 alleles) and MAOA-uVNTR (3 alleles) for
both genders in the patient and control groups were all in
Hardy-Weinberg equilibrium (data not shown).
Allele frequencies of MAOA-CA and -uVNTR polymor-
phism were compared between the BPD patients and
matched controls using the χ2 test and Fisher's exact test.
Rare alleles of MAOA-CA (frequency less than 5%) were
pooled together as a single allele, and MAOA- uVNTR was
classified in accordance with a previous classification [18]
Table 1: Distribution of MAOA – CA and uVNTR alleles in 103 
controls and 108 BPD patients.
Patients (frequency) Controls (frequency)
Allele Ma Fa Total Ma Fa Total
CA(bp)b
116 19 (0.42) 30 (0.37) 49 16 (0.41) 41 (0.47) 57
114 7 (0.15) 11 (0.14) 18 1 (0.03) 8 (0.09) 9
110 8 (0.17) 15 (0.19) 23 10 (0.25) 14 (0.16) 24
108 8 (0.17) 20 (0.25) 28 9 (0.23) 18 (0.20) 27
Others 4 (0.09) 4 (0.05) 8 3 (0.08) 7 (0.08) 10
Total 46 80 126 39 88 127
uVNTRc
Short 32 (0.60) 49 (0.52) 81 25 (0.48) 49 (0.58) 74
Long 21 (0.40) 45 (0.48) 66 27 (0.52) 35 (0.42) 62
Total 53 94 147 52 84 136
aM, Males; F, Females.
bDistribution of CA dinucleotide polymorphisms. Common alleles 
(frequency more than 5%) and the combined rare alleles were shown.
cDistribution of uVNTR polymorphism. The short allele is the 3 
repeats, and the long allele includes 4 and 5 repeats.Behavioral and Brain Functions 2008, 4:21 http://www.behavioralandbrainfunctions.com/content/4/1/21
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that repeats 4 and 5 were combined to be the long allele.
No differences were observed in single alleles or global
distributions of MAOA-CA and -uVNTR. The allelic distri-
butions of each marker are listed in Table 1.
Linkage disequilibrium measurement and risk haplotype 
analysis
Using haplotype analysis to investigate genetic associa-
tion has some advantages. First, it allows multiple poten-
tially causal loci to be tested simultaneously for
association. Second, haplotypes may be proxies for
untyped causal markers [35]. Once the haplotypes are
defined, it is straightforward to examine a subset of SNPs
and disease association. We select the 114 allele of
MAOA-CA and the short allele of functional MAOA-
uVNTR to comprise a 2-allele haplotype to examine its
risk for BPD. The 114S haplotype determined by combi-
nation of the most risk allele of MAOA-CA (114 allele)
and the transcriptionally less active short allele of MAOA-
uVNTR. Since MAOA  gene locates on X chromosome,
haplotypes were assigned to each individual male partici-
pant explicitly. The distribution of the 114S haplotype
was significantly different between male patients and con-
trols (Table 2; P = 0.01; Power = 75% when α = 0.05) and
associated with a risk to BPD (OR = 12.64, 95% CI = 0.69–
232.88). To test whether the 114S haplotype has distrib-
uted differently in female groups, the linkage disequilib-
rium coefficient values (D') of two polymorphisms were
calculated for females in patients (D' = 0.88) and controls
(D' = 0.78). The 114S haplotype was estimated to present
8 and 6 times in patients and controls, respectively, and
no differences in haplotype distribution between two
groups was evident in female (Table 2; P = 0.72). After the
correction for twice testing that were conducted in each
gender, the difference in male group is still significant (P
= 0.03).
Discussion
BPD is a common disease that is genetically heterogene-
ous with the same clinical manifestation caused by differ-
ent susceptibility genes or a combination of low
penetrating genes with possible environmental effect.
Analysis using mathematical modelling suggests the het-
erogeneous basis for the inheritance of bipolar disorders
[36]. For investigating these complex phenotypic traits
like BPD, current studies suggest that using association
analysis can have acceptable power to identify these small
genetic effects [37].
This study aims to investigate the MAOA gene effect on
BPD etiology in Han Chinese. The genetic association
between two polymorphisms of the MAOA gene and BPD
was conducted in 108 BPI patients and 103 normal con-
trols. To overcome the sample size limitation for detecting
small risk effect, we consider the two risk allele at the same
time and examine if there are any additive or interactive
risk for BPD. Growing evidences have supported the exist-
ence of higher-order risk interactions between or within
genes to cause common and complex diseases [33,38,39].
Previous study also showed a combination of several
common variants, that an association with disease at sin-
gle-locus levels are not significant, has a dramatic impact
on the etiology of complex diseases [33]. Using the haplo-
type based interaction-considered approach; we success-
fully identified a risk haplotype for BPD.
Significant risk haplotype effect was detected in male
groups but not in female groups. Our hypothesis of the
male-specific effect is the male only have single copy of
MAOA, thus the carrying of risk haplotype lead more con-
tribution to the diseased state. The gender effect of MAOA
in various psychiatric diseases has been discussed for a
long while. The first mutation in MAOA related to abnor-
mal behavior was seen in several males [8]. The MAOA
deficiency was associated with increased aggression; a
similar finding was made in male mice [10]. In addition,
many studies have reported finding significant gender-
specific associations with psychiatric diseases [14,27,40]
including BPD [27,28]. Collectively, these results suggest
that the MAOA mechanism underlying the etiology of
BPD might be different in males and females.
Just like other common psychiatric syndromes, BPD is
known to have complex etiology including effect of mul-
tiple pathogenic genes and non-genetic factors [41]. The
controversial results from previous association studies in
various populations [22,25,26] suggest the MAOA gene
and/or its interacting factors may have ethnic specificity in
BPD etiology. Although the risk haplotype of MAOA only
carried by few BPD patients and suggests that MAOA gene
may have only a small effect on the pathogenesis of BPD,
other studies have correlated MAOA with many human
Table 2: Risk haplotype distribution in BPD patients and controls.
Haplotype 114Sa Patients (freq.) Controls (freq.) P value Odds Ratio (95% Confidence Interval)
Males 6 (0.14) 0 (0.00) 0.01 12.64 (0.69–232.88) b
Female 8 (0.08) 6 (0.06) 0.72 1.22 (0.41–3.67)
aPower for the 114S haplotype distribution is about 74.9% with α = 0.05.
bSince odds ratio is undefined with zero cell, adding 0.5 to each cell was used for calculate the odds ratio for 114S haplotype.Behavioral and Brain Functions 2008, 4:21 http://www.behavioralandbrainfunctions.com/content/4/1/21
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behavioral traits that belong to the same spectrum with
BPD, including aggression [8], anxiety [42], depression
[14], and suicide [43]. Furthermore, the MAOA-knockout
mice showed aggressive behavior, which indicates a major
effect of MAOA deficiency. Taken together, these results
strongly suggest that MAOA is indeed involved in the
spectrum of diseases related to abnormalities of the cen-
tral nervous systems; however, the effect of MAOA on dif-
ferent diseases seems to be dissimilar.
Earlier studies indicated that there were 5 alleles of the
uVNTR polymorphism (2, 3, 3.5, 4, and 5; 30-bp repeats),
allele 3, 3.5, 4, and 5 were found in German population
[44], and in White/Non-Hispanic and African-American/
Black genotyping studies [18]. Another rare allele that has
two 30-bp repeats was found in Japanese, British Cauca-
sian, Swedish and Italian population [44-47]. Further-
more, the long alleles (4 and 5, 30-bp repeat) have been
reported to be transcriptionally more active than the short
allele (3, 30-bp repeat) [18]. In the present study, we
detected 3 alleles (3, 4, and 5) in people of Han Chinese
origin in Taiwan, and the major alleles are 3 and 4 repeats.
The observed allele distribution in this study is similar to
another report from Taiwan [14] and to a report from the
People's Republic of China [48]; all three together suggest
that this unique distribution pattern may be specific to
ethnic Chinese.
Strong linkage disequilibrium was observed between the
MAOA-uVNTR and MAOA-CA markers because these two
markers are only 24 Kb apart. The linkage disequilibrium
D' value suggests only a negligible level of recombination
in the population studied. The shorter MAOA-CA alleles
were found most frequently on the chromosome carrying
MAOA-uVNTR allele 4 or 5, whereas the longer MAOA-CA
alleles appeared most frequently on the chromosome car-
rying MAOA-uVNTR allele 3 (data not shown). This
result, however, is different from the previous report, in
which strong linkage disequilibrium was observed for
long MAOA-uVNTR with long MAOA-CA alleles and short
MAOA-uVNTR with short MAOA-CA alleles in the U.S.
population [18]. The discrepancies in allelic distribution
and phase of linkage disequilibrium might be attributable
to ethnic differences.
In the past few years, our series studies focus on the asso-
ciation of serotonergic genes with BPD, including the
serotonin synthetic enzymes TPH1 [31] and TPH2 [33],
the serotonin transporter SLC6A4 [30], and several serot-
onin receptors (HTRs) [32]. Those results together with
our findings in the current study support our hypothesis
that the serotonergic system has a major impact on the
pathogenesis of BPD. Although each of genes involved in
the serotonergic system may contribute only a small to
modest effect, their co-contribution with the environment
or other genetic or epigenetic factors may result in BPD.
Although our study suggested that MAOA might have a
small effect on susceptibility to BPD, the chance of false
positives cannot be excluded because of the sampling lim-
itations (i.e., small sample size and subject assessment
lacked support by structured interviews). Because of the
limitations, further investigations with larger populations
are required to elucidate the significance of MAOA on the
pathogenesis of BPD in Taiwan.
Conclusion
Results from this study suggest that MAOA may have a
gender-specific and small effect on the etiology of BPD in
Taiwan. We found that all male individuals carried 114S
risk haplotype appear in BPD group, but equally distrib-
ute on female patient and control groups. But due to the
limited sample size, results from this study need to be
confirmed by further investigations with larger popula-
tions.
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